A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II)

Objective: Comparison of stavudine (d4T), didanosine (ddl) and indinavir (I DV) with zidovudine (ZDV), lamivudine (3TC) and IDV in HIV-1 infected patie nts. Design: Randomized, open-label. Setting: Fourteen HIV Clinical Research Centers. Patients: Two-hundred and five patients with less than 4 weeks antiretrovir al treatment, naive to 3TC and protease inhibitors and with CD4 cell counts greater than or equal to 200 x 10(6)/l and plasma HIV-1 RNA levels greater than or equal to 10 000 copies/ml. Interventions: Stavudine 40 mg and ddl 200 mg twice daily plus IDV 800 mg e very 8 h compared with ZDV 200 mg every 8 h or 300 mg twice daily, 3TC 150 mg twice daily plus IDV. Main outcome measures: The proportion of patients with plasma HIV-1 RNA lev els < 500 copies/ml and less than or equal to 50 copies/ml and changes in C D4 cell counts were compared. Results: In an analysis of the primary endpoint, 61% of patients on d4T + d dl + IDV and 45% of patients on ZDV + 3TC + IDV had all HIV-1 RNA values ob tained between weeks 40 and 48 < 500 copies/ml [95% confidence interval (CI ) for the difference between proportions, 1.7-30.3%; P = 0.0381. In an inte nt-to-treat analysis, the percentage of all patients randomized with all HI V-1 RNA levels < 500 copies/ml between 40 and 48 weeks were 53% for the d4T + ddl + IDV arm and 41% for the ZDV + 3TC + IDV arm (95% Cl, -1.4% to 25.7 %; P = 0.068). At 48 weeks 41% and 35% were less than or equal to 50 copies /ml for the stavudine- and ZDV-containing arms respectively (P > 0.2). The median time-weighted average increases in CD4 cells count over 48 weeks wer e 150 x 10(6)/l cells for the d4T arm and 106 x 10(6)/l cells for the ZDV a rm (P = 0.001). The occurrence of serious adverse events was not significan tly different between arms. Conclusion: The combination of stavudine, ddl and IDV resulted in potent an tiretroviral effects over a 48-week period, comparable or superior to zidov udine, 3TC and IDV supporting the use of stavudine, ddl and a protease inhi bitor as an initial antiretroviral treatment. (C) 2000 Lippincott Williams & Wilkins.